Intracameral moxifloxacin minimizes risk of endophthalmitis

• Posted on: Jun 19 2019
• By: Saratoga Opthalmology
• Leave a response

This is the first prospective randomized clinical trial assessing the safety and efficacy of intracameral moxifloxacin for preventing post-cataract endophthalmitis.
Source: AAO

Posted in: Uncategorized